| Literature DB >> 32180339 |
Alexis J Perros1,2,3, Arlanna Esguerra-Lallen1,3,4, Kelly Rooks1, Fenny Chong1, Sanne Engkilde-Pedersen1,3,4, Helen M Faddy1,2,5,6, Elise Hewlett1, Rishendran Naidoo7, John-Paul Tung1,2,3,5, John F Fraser2,3,4, Peter Tesar7, Marc Ziegenfuss4, Susan Smith7, Donalee O'Brien7, Robert L Flower1,5, Melinda M Dean1,3,6.
Abstract
Coronary artery bypass grafting (CABG) triggers a systemic inflammatory response that may contribute to adverse outcomes. Dendritic cells (DC) and monocytes are immunoregulatory cells potentially affected by CABG, contributing to an altered immune state. This study investigated changes in DC and monocyte responses in CABG patients at 5 time-points: admission, peri-operative, ICU, day 3 and day 5. Whole blood from 49 CABG patients was used in an ex vivo whole blood culture model to prospectively assess DC and monocyte responses. Lipopolysaccharide (LPS) was added in parallel to model responses to an infectious complication. Co-stimulatory and adhesion molecule expression and intracellular mediator production was measured by flow cytometry. CABG modulated monocyte and DC responses. In addition, DC and monocytes were immunoparalysed, evidenced by failure of co-stimulatory and adhesion molecules (eg HLA-DR), and intracellular mediators (eg IL-6) to respond to LPS stimulation. DC and monocyte modulation was associated with prolonged ICU length of stay and post-operative atrial fibrillation. DC and monocyte cytokine production did not recover by day 5 post-surgery. This study provides evidence that CABG modulates DC and monocyte responses. Using an ex vivo model to assess immune competency of CABG patients may help identify biomarkers to predict adverse outcomes.Entities:
Keywords: Dendritic cells; cardiac surgery; coronary artery bypass; immune modulation; immunoparalysis; monocytes
Mesh:
Substances:
Year: 2020 PMID: 32180339 PMCID: PMC7176880 DOI: 10.1111/jcmm.15154
Source DB: PubMed Journal: J Cell Mol Med ISSN: 1582-1838 Impact factor: 5.310
Inclusion criteria for study enrolment
| Inclusion Criteria |
|---|
| Participant is scheduled for CABG |
| Participant has not received a transfusion of packed red blood cells or platelet concentrates in the past 5 days |
| Participant is not enrolled in any other research studies or clinical trials |
| Participant has not been diagnosed with human immunodeficiency virus, hepatitis c virus or hepatitis b virus infection |
| Participant is over the age of 18 |
| English is the participant’s primary language |
| Participant is not pregnant |
| Participant is not of Aboriginal or Torres Strait Islander descent |
| Participant is not highly dependent on medical care |
| Participant does not have a cognitive impairment, intellectual disability or a mental illness |
| Participant is not involved in illegal activity |
Patient demographic and clinical summary
| Patient characteristics summary (n = 49) | |||
|---|---|---|---|
| n | Mean | SD | |
| Patient characteristics | |||
| Age (years) | 49 | 68 | ±9 |
| Sex | |||
| Male | 44 | ||
| Female | 5 | ||
| History of smoking | 38 | ||
| History of diabetes | 20 | ||
| Clinical characteristics | |||
| Total LOS ICU (Hours) | 49 | 40 | ± 46 |
| Ventilation Time (Hours) | 49 | 9 | ± 5 |
| Development of Atrial Fibrillation | 17 | ||
| Development of Sternal Infection Development | 4 | ||
| Other Complications (eg respiratory failure, tamponade) | 7 | ||
Haematological parameters
| Patient haematological characteristics (n = 49) | ||||||
|---|---|---|---|---|---|---|
| Haematological characteristics | Admission | Operating theatre | ICU | Day 3 | Day 5 | Reference range |
| White blood cell count (x109/L) | 6.2 ± 2.2 | 10.0 ± 3.5 | 12.0 ± 4.3 | 12.6 ± 4.3 | 8.7 ± 2.3 | 4.0–11.0 |
| Red blood cell count (x1012/L) | 4.1 ± 0.6 | 3.3 ± 0.6 | 3.6 ± 0.8 | 3.7 ± 1.0 | 3.5 ± 0.9 | 3.6–6.0 |
| Platelet count (x109/L) | 216 ± 64 | 162 ± 44 | 196 ± 64 | 183 ± 50 | 252 ± 79 | 150–450 |
| Haemoglobin (g/L) | 131 ± 18 | 107 ± 20 | 116 ± 27 | 119 ± 31 | 112 ± 26 | 115–180 |
| Haematocrit (L/L) | 0.37 ± 0.05 | 0.31 ± 0.06 | 0.33 ± 0.07 | 0.34 ± 0.08 | 0.32 ± 0.08 | 0.33–0.52 |
| Mean cell volume (fL) | 90 ± 5 | 94 ± 5 | 91 ± 5 | 92 ± 5 | 91 ± 5 | 80–98 |
| Mean cell haemoglobin (pg) | 32.1 ± 2.2 | 33.6 ± 10.3 | 32.2 ± 2.2 | 32.4 ± 2.2 | 32.0 ± 2.3 | 27–35 |
| Mean cell haemoglobin concentration (g/L) | 355 ± 15 | 343 ± 15 | 352 ± 15 | 354 ± 15 | 352 ± 17 | 310–365 |
Repeated measures one‐way ANOVA with Dunnett’s post‐test indicated by: * P < 0.05;** P < 0.01;*** P < 0.001;**** P < 0.0001.
Data represent mean ± SD.
Figure 1Assessment of monocyte and DC‐specific activation profile following CABG. Open grey squares indicate monocytes and open purple circles indicate DC. Y‐axis indicates the log2 fold changed data. X‐axis indicates sample collection time‐point (Admission (Admin)) and peri‐operative (OT), ICU, D3, D5). Data from 49 CABG patients. Symbols and bars at each time‐point represent mean ± SEM. As monocyte and DC expression of CD38 and CD86 approached 100%, changes in the expression were assessed using MFI. ANOVA indicated by horizontal bar with P value above. An asterisk indicates P value for monocytes and a hash indicates P value for DC. Dunnett’s post‐test (admission vs. sample time‐point) is indicated at specific time‐points by an asterisk for monocytes or hash for DC as follows: *(or #) P < 0.050, **(or ##) P < 0.010, ***(or ###) P < 0.001, ****(or ####) P < 0.0001
Figure 2Assessment of the monocyte and DC‐specific immune profile following CABG. Open blue squares indicate monocytes and open red circles indicate DC. Y‐axis indicates the log2 fold change data. X‐axis indicates sample collection time‐point (Admission (Admin)) and peri‐operative (OT), ICU, D3, D5). Data from 49 CABG patients. ANOVA indicated by horizontal bar with P value above. An asterisk indicates P value for monocytes and a hash indicates P value for DC. Dunnett’s post‐test (admission vs. sample time‐point) is indicated at specific time‐points by an asterisk for monocytes or hash for DC as follows: *(or #) P < 0.050, **(or ##) P < 0.010, ***(or ###) P < 0.001, ****(or ####) P < 0.0001
Figure 3Assessment of monocyte and DC‐specific activation profile following CABG in a model of bacterial infection. Closed grey squares indicate monocytes and closed purple circles indicate DC. Y‐axis indicates the log2 fold changed data. X‐axis indicates sample collection time‐point (Admission (Admin)) and peri‐operative (OT), ICU, D3, D5). Data from 49 CABG patients. Symbols and bars at each time‐point represent mean ± SEM. As monocyte and DC expression of CD38 and CD86 approached 100%, changes in the expression were assessed using MFI. ANOVA indicated by horizontal bar with P value above. An asterisk indicates P value for monocytes and a hash indicates P value for DC. Dunnett’s post‐test (admission vs. sample time‐point) is indicated at specific time‐points by an asterisk for monocytes or hash for DC as follows: *(or #) P < 0.050, **(or ##) P < 0.010, ***(or ###) P < 0.001, ****(or ####) P < 0.0001
Figure 4Assessment of the monocyte and DC cytokine production following CABG in a model of bacterial complications. Closed blue squares indicate monocytes and closed red circles indicate DC. Y‐axis indicates the log2 fold change data. X‐axis indicates sample collection time‐point (Admission (Admin)) and peri‐operative (OT), ICU, D3, D5). Data from 49 CABG patients. Symbols and bars at each time‐point represent mean ± SEM. ANOVA indicated by horizontal bar with P value above. An asterisk indicates P value for monocytes and a hash indicates P value for DC. Dunnett’s post‐test (admission vs. sample time‐point) is indicated at specific time‐points by an asterisk for monocytes or hash for DC as follows: *(or #) P < 0.050, **(or ##) P < 0.010, ***(or ###) P < 0.001, ****(or ####) P < 0.0001